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S U M M A R Y
Objectives: To evaluate the efﬁcacy and safety of using hepatitis B immunoglobulin (HBIG) during
pregnancy to prevent hepatitis B virus (HBV) mother-to-child transmission (MTCT).
Methods: We systematically reviewed the effect of HBIG in decreasing HBV MTCT from randomized
controlled trials (RCTs) carried out between January 1990 and December 2008, in English and Chinese
languages. Multiple databases were searched, and experts in this ﬁeld were contacted. The
methodological quality of each RCT was assessed by the Jadad score. We abstracted data on HBV
intrauterine infection, MTCT, treatment methods, newborn immune prophylaxis methods, and adverse
effects. A Mantel–Haenszel random-effects model was employed for all analyses using odds ratios (OR)
and 95% conﬁdence intervals (95% CI).
Results: Five thousand nine hundred newborns of asymptomatic hepatitis B surface antigen (HBsAg)-
seropositivemothers from 37 qualiﬁed RCTswere included. Comparedwith the control group, newborns
in the HBIG group had a lower intrauterine infection rate (indicated by HBsAg as OR 0.22, 95% CI [0.17,
0.29], from 32 RCTs; indicated by HBV DNA as OR 0.15, 95% CI [0.07, 0.30], from 13 RCTs; p < 0.01 for
both) and a higher protection rate (indicated by hepatitis B surface antibody (HBsAb) as OR 11.79, 95% CI
[4.69, 29.61], from 15 RCTs; p < 0.01). The same trend was found in MTCT by the time of 9–12 months
after birth, indicated by HBsAg (OR 0.33, 95% CI [0.21, 0.51], from nine RCTs; p < 0.01) and HBsAb (OR
2.49, 95% CI [1.55, 4.01], from 11 RCTs; p < 0.01). HBIG appears to be safe, but a few RCTs have reported
adverse events.
Conclusion: Multiple injections of HBIG in HBV carrier mothers with a high degree of infectiousness in
late pregnancy, effectively and safely prevent HBV intrauterine transmission.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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TheWorld Health Organization (WHO) reports that, worldwide,
there are over two billion people who have a past or present
hepatitis B virus (HBV) infection, and 350 million of them are
chronic HBV carriers.1 Mother-to-child transmission (MTCT)
accounts for 40–50% of HBV carriers.2 Joint HBV immune
prophylaxis with hepatitis B vaccine (HBVac) and hepatitis B
immunoglobulin (HBIG) beginning after birth, generally interrupts
HBV MTCT during and after labor, and is recommended by the
WHO, World Gastroenterology Organisation (WGO), and the US
Centers for Disease Control and Prevention (CDC); however, none
of these organizations have mentioned any schedule of HBIG
medication in pregnant HBV carrier mothers.3–5 Of the offspring of* Corresponding author. Tel.: +1 215 204 9999.
E-mail address: szj771222tmd@163.com (Z. Shi).
1 Zhongjie Shi and Xiaomao Li, contribute equally to this paper.
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.09.008HBV carrier mothers, 1–8% suffer from HBV infection in their early
life, even after they have received routine joint immune
prophylaxis, because they were already infected in utero.6,7
It has been suggested that multiple small doses of HBIG
intramuscular injection in HBV carrier mothers during pregnancy
can effectively reduce intrauterine infection, which might be due
to the reduced maternal HBV DNA load or the development of the
newborn’s passive immunity. However, even when treated with
HBIG, the intrauterine infection rate is not signiﬁcantly reduced in
women with a high HBV DNA serum load.8 Moreover, there
remains controversy regarding the efﬁcacy (whether there is the
same efﬁcacy in HBV carrier mothers with different degrees of
infectiousness), safety (HBIG derives from blood), and HBV
mutation-generating effects of HBIG.
We systematically reviewed the efﬁcacy of HBIG treatment
during late pregnancy together with joint immune prophylaxis
after birth versus joint immune prophylaxis alone, in decreasing
HBVMTCT, and investigated the safety of HBIG in pregnantwomen
and their newborns.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Study description
We searched the databases of Medline, EMBASE, the Cochrane
Library, the National Science Digital Library (NSDL), and the China
Biological Medicine Database (CBMdisc), January 1990 to Decem-
ber 2008, for relevant randomized controlled trials (RCTs) in the
English language and Chinese peer-reviewed literature. Articles on
an HBIG regimen in pregnant asymptomatic HBV carrier mothers,
aimed at decreasing the risk of HBVMTCT, compared with placebo
or no intervention during pregnancy (control), were sought.
Keywords employed were HBIG (or hepatitis B immunoglobulin)
and HBV (or hepatitis B virus) and intrauterine (or pregnant or
pregnancy or mother or children or infant or newborn). We also
hand-searched the bibliographies of the original studies, reviews
(including meta-analyses), and relevant conference abstracts, and
contacted some investigators in this ﬁeld. The included RCTs were
also required to have a clear description of HBV intrauterine
transmission and MTCT, characteristics of the enrolled mothers, a
description of recruitment methods, details of HBIG medication,
newborn and infant immune prophylaxis schedules, and follow-up
of bothmothers and their children. Generally, HBV carrier mothers
in the treatment group received 100–400 IU HBIG intramuscular
injections once a month from 28 weeks of gestation or later for a
total of three doses. All newborns (both in the treatment group andFigure 1. Flow chart ofcontrol group) receivedHBIG andHBVac joint immune prophylaxis
after birth, as recommended by the WHO.
Two authors independently selected relevant studies and made
a post-hoc assessment of methodological quality by means of the
Jadad score, a procedure to independently assess the methodolog-
ical quality of clinical trials, the score of which is between zero
(very poor quality) and 5 (rigorous).9 Questionable RCTs were
discussed among all authors and/or further contact wasmadewith
the authors of the original RCTs to determine inclusion. The
included mothers were all hepatitis B surface antigen (HBsAg)-
positive and asymptomatic, without other diseases or medications
during pregnancy. We abstracted data on study design and
methods, inclusion and exclusion criteria, characteristics of
patients, duration and dosage of HBIG regimens, outcomes,
complications, and adverse events. Since HBV mothers with
HBeAg and/or HBV DNA seropositivity have a higher degree of
infectiousness, we sub-divided each comparison according to
these indices.
2.2. End points and deﬁnitions
For primary outcomes, we estimated the rate of infant HBV
infection (indicated by HBsAg or HBV DNA) or protection
(indicated by hepatitis B surface antibody (HBsAb), the observed
proportion) at various time-points (within 24 h after birth and at
9–12 months of age). In the included RCTs, the diagnosis of HBVanalysis procedure.
Table 1
Characteristics of randomized controlled trials
Reference RCTa Maternal HBIG treatment Newbornb 9–12 month infantb
HBeAg DNA Dose Time HBsAg-pos DNA-pos HBsAb-pos HBsAg-pos DNA-pos HBsAb-pos Jadad
score
1. Chen 2003 +/ +/ 200 IU 28, 32, 36 weeks U 1/26:2/20d 2/3g
U 2/18:6/15e
U 3/14:8/12f
2. Chen 2006 N N 200 IU 28, 32, 36 weeks 5/45:10/40 3/45:5/40 3
3. Chen 2006-II +/ N 200 IU 28, 32, 36 weeks U 1/34:5/36d 3
U 4/16:9/14e
4. Chen 2007c + N 200 IU 28, 32, 36 weeks U 1/45:13/49e U 14/45:4/49e 1/45:13/49e 33/45:35/44e 3
5. Chi 2002 +/ N 200 IU 28, 32, 36 weeks 0/42:2/43d 21/69:7/72 3
4/27:10/29e
6. Dai 2004 N N 200 IU 30, 34, 38 weeks U 1/86:35/70 U 57/86:1/70 3
7. Guo 2006c N N 200 IU 28, 32, 36 weeks 2/45:9/43 42/45:33/43 3
8. Han 2003c +/ N 200 IU 28, 32, 36 weeks 3/43:9/38d 102/126:0/90 5/126:12/90 121/126:78/90 3
21/80:23/52e
9. Ji 2003 N N 200 IU 28, 32, 36 weeks U 3/29:5/31 U 10/29:3/31 2/3g
10. Ji 2007 +/ N 200 IU 28, 32, 36 weeks 3/83:5/84d 1/83:3/84d 107/113:83/110 3
2/30:10/26e 1/30:6/26e
11. Jia 2001 +/ +/ 200 IU 28, 32, 36 weeks 0/25:3/30d 3
1/15:7/16e
1/20:10/22f
12. Li 2003 +/ N 200 IU 28, 32, 36 weeks 3/56:8/52 4
13. Li 2004 N N 200 IU 28, 32, 36 weeks 2/57:2/55 4/57:13/55 4
14. Li 2006 N N 200 IU 28, 32, 36 weeks 13/206:40/253 11/206:37/253 3
15. Liang 2004 N + 200 IU 28, 32, 36 weeks 5/62:23/60f 3
16. Lin 2004 +/ N 200 IU 28, 32, 36 weeks 7/55:20/62 17/55:5/62 3/53:8/62 33/53:16/62 3
17. Liu 2007c +/ N 200 IU 28, 32, 36 weeks 1/31:1/34d 12/31:12/34d 0/31:1/34d 24/31:25/34d 3
1/12:2/9e 4/12:1/9e 0/12:2/9e 10/12:4/9e
18. Luo 2004 N N 200 IU 28, 32, 36 weeks U 3/60:13/40 U 5/60:17/40 U 22/60:0/40 3
19. Pan 2006 +/ N 200 IU 28, 32, 36 weeks U 2/50:3/50 U 3/50:4/50 3
20. Shi 2009 N +/ 200 IU 28, 32, 36 weeks 8/146:15/84 4/116:5/43f 5
8/116:10/43f
21. Su 2000c +/ N 200 IU 28, 32, 36 weeks 0/22:2/25d 24/26:17/18 3
3/23:8/18e
22. Sui 2002 N N 100 IU 28, 32, 36 weeks 0/58:11/52 6/58:18/52 53/58:6/52 3
23. Xing 2003c +/ +/ 200 IU 28, 32, 36 weeks 0/30:3/25d 27/28:21/24 3
2/16:6/15e
2/22:9/20f
24. Xu 2004c N N 200 IU 28, 32, 36 weeks 1/45:9/44 0/45:6/44 8/45:1/44 1/45:10/44 0/45:5/44 39/45:30/44 3
25. Xu 2006 + N 200 IU 28, 32, 36 weeks U 7/28:20/24e 4
26. Yang 2006 +/ +/ 200IU 28, 32, 36d/28, 30,
32, 34, 36, 38e weeks
2/46:14/32d 0/46:0/32d 10/46:0/32d 3
12/117:48/90e 14/117:77/90e 7/117:0/90e
27. Yu 2005 N N 200 IU 28, 32, 36 weeks U 3/60:13/40 3
28. Yu 2006 +/ N 200 IU 28, 32, 36 weeks 0/40:2/20d 10/55:0/28 3
8/15:8/8e
29. Yu 2008 +/ +/ 200 IU 28, 32, 36 weeks U 1/28:9/33 U 1/28:7/33 3
30. Yuan 2006 + N 400 IU 28, 32, 36 weeks 27/118:32/133e 0/118:0/133e 13/118:17/133e 101/118:112/133e 4
31. Yue 1999 N N 200 IU 28, 32, 36 weeks 0/35:3/14 32/35:0/14 4
32. Zhang 2005 +/ N 200 IU 28, 32, 36d/24, 28,
32, 36e weeks
2/58:16/49d 3
3/56:19/40e
33. Zhang 2007 N N 200 IU 28, 32, 36 weeks 11/163:54/157 3
34. Zheng 2005 N + 200 IU 28, 32, 36 weeks U 7/92:28/92f 3
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Z. Shi et al. / International Journal of Infectious Diseases 14 (2010) e622–e634 e625intrauterine infection and MTCT were deﬁned as neonatal
peripheral or umbilical blood HBsAg- or HBV DNA-seropositive
at birth and at 9–12 months old, respectively. Protection against
HBV was determined by detection of HBsAb at birth and at 9–12
months of age. Secondary outcomes included treatment methods,
newborn immune prophylaxis schedules, and adverse effects in
both pregnantmothers (such as transaminase increase, intolerance
to treatments, complications in pregnancy and during delivery)
and their newborns (such as 1-min Apgar score and developmental
indices).
2.3. Statistical analysis
Statistical analyses were done by use of Review Manager
version 5.0 software, devised by the Cochrane Collaboration.
Pooled odds ratios (OR) and 95% conﬁdence intervals (CI) were
determined by use of a Mantel–Haenszel random-effects model
shown in forest plots. In the case of a cell with zero events in an
individual study, the OR was calculated with 0.5 added to the
zero cell. Statistical between-study heterogeneity was assessed
by Chi-square test and I2 measurement. Publication bias was
assessed by funnel plot. Differences between subgroups were
assessed on the basis of the Chi-square statistic. For all tests
done, a p-value of less than 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Patients
Thirty-seven RCTs on HBIG application in late pregnancy aimed
at interrupting HBV MTCT, published in Chinese and English, were
included in the ﬁnal analysis (Figure 1); there were 5900 infants,
3062 in the HBIG treatment group and 2838 in the control group
(without intervention or with placebo) (Table 1).8,10–45
3.2. Newborn HBsAg seropositivity
Altogether there were 2850 newborns in the HBIG group and
2644 newborns in the control group, included in 32 RCTs.
Disregardingmaternal HBVDNA status, therewere 2730 newborns
in the HBIG group and 2598 newborns in the control group. The
pooled OR (95% CI) comparing these two groups for newborn
HBsAg seropositivity was 0.22 (0.17, 0.29), and a medium level of
heterogeneity was observed (I2 =43%). In the maternal HBeAg-
negative subgroup, there were 840 newborns in the HBIG group
and 790 newborns in the control group, included in 13 RCTs, with
OR (95% CI) being 0.21 (0.13, 0.34) (I2 = 0%). In thematernal HBeAg-
positive subgroup, there were 827 newborns in the HBIG
treatment group and 774 newborns in the control group, included
in 16 RCTs, with OR (95% CI) being 0.24 (0.15, 0.38) (I2 = 60%). In the
subgroup where maternal HBeAg status was not mentioned (the
subgroup named ‘others’), there were 1063 newborns in the HBIG
group and 1034 newborns in the control group, included in 16
RCTs, with OR (95% CI) being 0.20 (0.12, 0.32) (I2 = 42%) (Table 2).
When maternal HBV DNA-positive, there were 216 newborns in
the HBIG treatment group and 141 newborns in the control group,
included in four RCTs, with OR (95% CI) being 0.23 (0.12, 0.44)
(I2 = 0%) (Table 2s). Publication bias was shown by a funnel plot
(Figure 2).
3.3. Newborn HBV DNA seropositivity
In total there were 1004 newborns in the HBIG group and 893
newborns in the control group who had data on their serum HBV
DNA status, included in 13 RCTs. Disregarding maternal HBV DNA
Table 2
Newborn HBV intrauterine infection according to HBsAg positivity
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Table 2s
Newborn HBV intrauterine infection according to HBsAg positivity
Z. Shi et al. / International Journal of Infectious Diseases 14 (2010) e622–e634 e627status, there were 734 newborns in the HBIG group and 698
newborns in the control group. The pooled OR (95% CI) comparing
these two groups for newborn HBsAg seropositivity was 0.15 (0.07,
0.30), and a high level of heterogeneity was observed (I2 = 68%). In
the maternal HBeAg-negative subgroup, there were 72 newborns
in the HBIG group and 52 newborns in the control group, included
in two RCTs, with an OR (95% CI) of 0.36 (0.03, 4.28). In the
maternal HBeAg-positive subgroup, there were 163 newborns in
the HBIG group and 129 newborns in the control group, included in
three RCTs, with an OR (95% CI) of 0.05 (0.02, 0.18) (I2 = 61%). In the
‘others’ subgroup, there were 499 newborns in the HBIG group and
517 newborns in the control group, included in seven RCTs, with
OR (95% CI) being 0.24 (0.16, 0.38) (I2 = 0%) (Table 3, Figure 3).
When maternal HBV DNA-positive, there were 284 newborns inFigure 2. Funnel plots for Table 2 and Table 2s.the HBIG treatment group and 207 newborns in the control group,
included in four RCTs, with OR (95% CI) being 0.18 (0.10, 0.32)
(I2 = 0%) (Table 3s).
3.4. Infant HBsAg seropositivity at 9–12 months
There were 1079 infants in the HBIG group and 1070 infants in
the control group who had data on their serum HBsAg status at 9–
12months of age, included in nine RCTs, with a pooled OR (95% CI)
of 0.33 (0.21, 0.51) (I2 = 19%). When maternal HBeAg-negative,
there were 114 infants in the HBIG group and 118 infants in the
control group, included in two RCTs, with an OR (95% CI) of 0.34
(0.05, 2.18) (I2 = 0%). When maternal HBeAg-positive, there were
205 infants in the HBIG group and 217 infants in the control group,
included in four RCTs, with an OR (95% CI) of 0.21 (0.04, 1.03)
(I2 = 65%). In the ‘others’ subgroup, there were 760 infants in the
HBIG group and 735 infants in the control group, included in ﬁve
RCTs, with OR (95% CI) being 0.32 (0.21, 0.49) (I2 = 0%) (Table 4,
Figure 4).
3.5. Newborn HBsAb seropositivity
Altogether 1037 newborns in the HBIG treatment group and
900 newborns in the control group had data on their serum HBsAb
status, included in 15 RCTs, with a pooled OR (95% CI) of 11.79
(4.69, 29.61) (I2 = 79%). When maternal HBeAg-negative, there
were 77 newborns in the HBIG group and 66 newborns in the
control group, included in two RCTs, with an OR (95% CI) of 3.47
(0.20, 61.54) (I2 = 73%). When maternal HBeAg-positive, there
were 292 newborns in the HBIG treatment group and 281
newborns in the control group, included in four RCTs, with OR
(95% CI) being 5.43 (1.98, 14.85) (I2 = 0%). In the ‘others’ subgroup,
there were 668 newborns in the HBIG treatment group and 553
newborns in the control group, included in 11 RCTs, with OR (95%
CI) being 18.34 (5.63, 59.72) (I2 = 81%) (Table 5, Figure 5).
3.6. Infant HBsAb seropositivity at 9–12 months
Therewere 693 infants in the HBIG group and 665 infants in the
control group who had data on their serum HBsAb status at 9–12
months of age, included in 11 RCTs, with pooled OR (95% CI) being
2.49 (1.55, 4.01) (I2 = 50%). When maternal HBeAg-positive, there
were 175 infants in the HBIG group and 186 infants in the control
group, included in three RCTs, with OR (95% CI) being 1.20 (0.52,
2.79) (I2 = 45%). In the ‘others’ subgroup, there were 487 infants in
the HBIG group and 445 infants in the control group, included in
Table 3
Newborn HBV intrauterine infection according to HBV DNA positivity
Z. Shi et al. / International Journal of Infectious Diseases 14 (2010) e622–e634e628eight RCTs, with OR (95% CI) being 4.01 (2.66, 6.06) (I2 = 0%)
(Table 6, Figure 6).
The above analyses showed a generally signiﬁcant reduction of
HBV MTCT and a signiﬁcantly higher HBV protection rate in the
HBIG group both at birth and at 9–12 months after delivery
(Table 7). In the short-term (at the time-point of birth), HBIG
effectively interrupted HBV intrauterine infection. In the long-
term, HBIG effectively interrupted HBV MTCT when HBV carrier
mothers had a high HBV degree of infectiousness.
3.7. Secondary outcomes
There were some differences in treatment doses and schedules
in the different subgroups. Maternal HBeAg and HBV DNA status
representative of the degree of infectiousness were described in a
portion of the RCTs (Table 1). Few RCTs reported adverse effects in
pregnant mothers or newborns.
4. Discussion
4.1. Diagnosis of HBV intrauterine infection
The diagnoses of HBV intrauterine infection include: (1) serum
HBsAg-positive and/or HBeAg-positive, or HBV DNA-positive after
birth; (2) serum HBsAg-positive and/or HBeAg-positive, or HBV
DNA-positive after birth, lasting more than two months;46 (3)
persistent serum anti-HBc IgM-positive after birth;47 (4) continu-
ous three out of four serum samples HBsAg-positive, includingwithin 24 h after birth, and at 1, 6, and 12months of age.48 All RCTs
in our analysis referred to the ﬁrst diagnosis.
4.2. Interpretation of results
Although in the maternal HBeAg-negative subgroup, and even
in the maternal HBeAg-positive subgroup, HBIG treatment had no
statistical signiﬁcance in the interruption of HBV MTCT at 9–12
months of age, HBIG showed its signiﬁcance in the pooled
comparison results. Considering the reduced heterogeneity in
the pooled comparison and the relatively smaller number of cases
in each subgroup, it might be reasonable to assume that the pooled
results apply to those subgroups as well. It is known that although
HBeAg indicates a higher degree of infectiousness, there are still
certain HBV carriers who are HBeAg-seropositive but have a low
degree of infectiousness, and vice versa.49 HBV DNA is more
accurate in predicting the degree of infectiousness, because its
seropositivity is proof of HBV active replication. Unfortunately, few
RCTs reported MTCT of HBV with regard to maternal HBV DNA
status. Because maternal HBeAg and HBV DNA do not always
coincide, we reported maternal HBV DNA-positive newborns
separately from the pooled analysis to avoid duplication of cases.
4.3. HBIG in interruption of HBV intrauterine infection
HBIG contains high levels of antibody to HBsAg. A prospective
study administeredmultiple HBVac intramuscular injections along
with HBIG to HBsAg-positive mothers from 20 weeks of gestation,
Figure 3. Funnel plots for Table 3 and Table 3s.
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newborn passive immunization.50 The possible mechanism is that
HBsAb can bind HBsAg, activate the complement system, facilitate
humoral immunity, reduceHBV level in pregnantmothers, prevent
and reduce the infection of normal cells, and reduce replication of
HBV. It might also be related to the passive immunization obtained
from pregnant mothers.51 These mechanisms have been chal-
lenged by Xiao et al.52 and Han et al.53 The former reported HBIG’s
efﬁcacy in the interruption of intrauterine infection, but found no
signiﬁcant increase in the newborn HBsAb seropositivity rate. The
latter found no signiﬁcant decrease inmaternal HBV DNA load, and
none of their newborns obtained HBsAb. Our meta-analysis solved
this controversy by showing a signiﬁcant increase in the newbornTable 3s
Newborn HBV intrauterine infection according to HBV DNA positivityHBsAb seropositivity rate and a lower intrauterine infection rate in
the HBIG group based on more patients when maternal HBV DNA
was also positive.
The biggest controversy is whether 100 or 200 IU of HBIG
injections at 1-month intervals are effective in decreasing
maternal HBV load or enabling HBIG to enter the fetal circulation
through the placenta, because it needs a continuous blood
concentration of 100–500 IU/l of HBIG to neutralize HBV in the
blood, even after the HBV-producing liver has been replaced by a
healthy one.54 However, several studies have found a signiﬁcant
decrease in maternal HBV DNA21,28 and HBsAg titer.39,44 Yu et al.36
found that an additional injection of 200 IU HBIG at labor onset
signiﬁcantly decreased both maternal HBV DNA and HBsAg titer,
and induced newborn HBsAb, compared with the 28–32–36weeks
HBIG treatment group or control group. They also showed that
within 3–7 days after HBIG injection, both maternal HBV DNA and
HBsAg decreased, while at 1 month after HBIG injection, maternal
HBV DNA and HBsAg returned to the level before injection. Based
on these ﬁndings, they proposed that the interruption of HBV
intrauterine infection with HBIG was mainly due to HBIG
transportation through the placenta, and less likely due to the
reduced maternal HBV load.
Another concern is whether massive HBIG injections in HBV
carrier mothers might cause HBV mutation, which would be
resistant to current HBVac. Yu et al.36 showed that there was no
signiﬁcant increase in the HBV mutation rate in HBV-infected
newborns in the HBIG group. There was no report of HBVmutation
in patients treated with HBIG at a total dosage of less than
20 000 IU and within 2 months. Since HBV intrauterine transmis-
sion occurs mainly during the third trimester, andmost of the fetal
organs have developed into shape by that time, which may be
inﬂuenced least during pregnancy,21 it is reasonable to apply HBIG
in pregnant mothers in late pregnancy with a limited amount and
for a limited duration.
Few RCTs reported sufﬁciently on adverse events. It should also
be noted that HBIG and the plasma-derived HBVac have the
potential for transmission of blood-borne infections. RCTs may
overlook adverse events because of the relatively low numbers of
participants or poor reporting of adverse events.
4.4. Inﬂuencing factors
Clinically, HBV infection is diagnosed by HBsAg seropositivity
or HBV DNA seropositivity, and patients in these two categories do
not have complete coincidence. To avoid this, the exact number of
Table 4
Infant HBV infection at 9–12 months according to HBsAg positivity
Z. Shi et al. / International Journal of Infectious Diseases 14 (2010) e622–e634e630HBV infection cases should be reported as HBsAg-positive and/or
HBV DNA-positive, as was reported by Li et al.,8 which is more
practical and accurate in diagnosing HBV infection. Many studies
have shown that the decisive factor in HBV MTCT is maternal HBV
viremia level.55 Maternal serum HBeAg or HBV DNA status in each
study should also be considered. Ngui et al.56 showed that when
maternal HBVDNAwas higher than 108 copies/ml, the intrauterine
infection rate was signiﬁcantly higher.
In our analysis, the schedules of joint immune prophylaxis
with HBVac and HBIG injections in different studies were
commonly recommended.3–5 Since most infant HBV infection
occurs before 1 year of age,57 all studies tested peripheral serumFigure 4. Funnel plot for Table 4.of these infants at 9–12 months of age to determine the results
of HBV MTCT and joint immune prophylaxis. The effective
component in HBVac is deactivated HBsAg protein, which is the
object of HBIG, and this might inﬂuence the immunogenicity of
HBVac. However, Beasley et al.58 argued that the existence of
passive antibody would not inhibit the immune response to the
vaccine.
4.5. Bias, heterogeneity, and quality of enrolled RCTs
The included RCTs with a Jadad score of 3 points or above were
all carried out in China, where the HBV prevalence might be
different from that in other regions. The quality of journals should
also be taken into account, although all the included journal
sources were peer-reviewed. We searched studies only in English
and Chinese languages, which might render a selection bias.
Publication bias, which is due to a desire to publish positive or
effective results by journals or researchers, can be shown by funnel
plot,59 and should also be taken into consideration. In our analysis,
the estimated OR is likely biased in favor of the intervention group
due to publication bias.
The heterogeneity of each analysis ranged from low (0%) to high
(79%). Theoretically, heterogeneity would decrease if subgroups
were divided according to risk factors.60 However, even though
heterogeneity did decrease in the maternal HBeAg-negative
subgroup, it increased in the HBeAg-positive group and some of
the ‘other’ group. Again this can be explained by the lower value of
HBeAg as an indicator of degree of infectiousness compared with
HBVDNA. The heterogeneitywas lowwith regard tomaternal HBV
Table 5
Newborn HBsAb positivity
Z. Shi et al. / International Journal of Infectious Diseases 14 (2010) e622–e634 e631DNA seropositivity, suggesting that when allocating HBV carrier
mothers into treatment or control groups in future RCTs, their HBV
DNA status should also be considered to make the efﬁcacy of HBIG
more convincing. Some analyses included few RCTs and a small
number of newborns or infants, which might explain why dividingFigure 5. Funnel plot for Table 5.into subgroups improved heterogeneity but lowered the power of
statistical tests. In order to evaluate the application of HBIG in
pregnant mothers, more RCTs that accurately describe maternal
HBV DNA status (ideally quantitatively) are needed for further
investigations and more convincing results.Figure 6. Funnel plot for Table 6.
Table 6
Infant HBsAb-positive at 9–12 months
Table 7
Summary of meta-analysis results
Results Maternal HBsAg-pos and HBeAg-
nega
HBsAg-pos and HBeAg-pos Others HBsAg-pos and HBV DNA-pos
OR
(95% CI)
No.
RCTsb
Casesc I2 OR
(95% CI)
No.
RCTsb
Casesc I2 OR
(95% CI)
No.
RCTsb
Casesc I2 I2d OR
(95% CI)
No.
RCTsb
Casesc I2
Newborn
HBsAg-pos 0.21
(0.13,
0.34)
13 1630 0% 0.24
(0.15,
0.38)
16 1601 60% 0.20
(0.12,
0.32)
16 2097 42% 43% 0.23
(0.12,
0.44)
4 357 0%
HBV DNA-pos 0.36
(0.03,
4.28)
2 124 - 0.05
(0.02,
0.18)
3 292 61% 0.24
(0.16,
0.38)
7 1016 0% 68% 0.18
(0.10,
0.32)
4 491 0%
HBsAb-pos 3.47
(0.20,
61.54)
2 143 73% 5.43
(1.98,
14.85)
4 573 0% 18.34
(5.63,
59.72)
11 1221 81% 79% -
Infants
HBsAg-pos 0.34
(0.05,
2.18)
2 232 0% 0.21
(0.04,
1.03)
4 422 65% 0.32
(0.21,
0.49)
5 1495 0% 19% -
HBV DNA-pos - - 0.08
(0.00,
1.47)
1 89 - - -
HBsAb-pos 1.23
(0.40,
3.84)
1 35 - 1.20
(0.52,
2.79)
3 361 45% 4.01
(2.66,
6.06)
8 932 0% 50% -
OR, odds ratio; CI, conﬁdence interval; RCT, randomized control trial; HBIG, hepatitis B immunoglobulin; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen;
HBsAb, hepatitis B surface antibody.
a Data in italic showed no signiﬁcant HBIGHBV interrupting rate (indicated by OR (95% CI) of HBIG vs. control group in HBsAg or HBVDNA seropositivity) or HBV protection
rate (indicated by HBsAb seropositivity). However, those data included fewer RCTs and much fewer cases, whose results should be further evaluated.
b Number of RCTs included.
c Cases in both the HBIG group and the control group.
d Pooled I2.
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Z. Shi et al. / International Journal of Infectious Diseases 14 (2010) e622–e634 e633In summary, our meta-analysis provides strong evidence that
multiple small doses of HBIG injection in late pregnancy, along
with joint immune prophylaxis beginning after birth, is effective
and safe in the interruption of HBV intrauterine infection and
MTCT in HBV carrier mothers with a high degree of infectiousness
comparedwith joint immune prophylaxis alone. For asymptomatic
HBV carrier mothers, we also recommend the above-mentioned
HBIG administration as a complementary treatment to the routine
immune prophylaxis in their newborns, beginning after birth.
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